Author: Ita, Kevin
Title: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development Cord-id: zhkg1hm2 Document date: 2020_9_10
ID: zhkg1hm2
Snippet: The Coronavirus disease 2019 (COVID-19) pandemic has spread to almost all nooks and corners of the world. There are numerous potential approaches to pharmacologically fight COVID-19: small-molecule drugs, interferon therapies, vaccines, oligonucleotides, peptides, and monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being use
Document: The Coronavirus disease 2019 (COVID-19) pandemic has spread to almost all nooks and corners of the world. There are numerous potential approaches to pharmacologically fight COVID-19: small-molecule drugs, interferon therapies, vaccines, oligonucleotides, peptides, and monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being used for the identification of B cell and cytotoxic T lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or β-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are being designed and moved into clinical trials, these types of vaccines are yet to be approved by regulatory bodies for human use. This review focuses on the drugs and vaccines being developed against the COVID-19.
Search related documents:
Co phrase search for related documents- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- action mechanism and adaptive immune system: 1
- action mechanism and adenosine analog: 1, 2
- action mechanism and adenovirus vector: 1
- action mechanism and live vaccine: 1, 2
- action mechanism and loading dose: 1, 2
- action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and lopinavir ritonavir treatment: 1, 2
- action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- active site and acute ards respiratory distress syndrome: 1, 2
- active site and acute respiratory distress: 1, 2, 3
- active site and adaptive immune system: 1
- active site and adenosine analog: 1, 2, 3
- active site and live vaccine: 1
- active site and loading dose: 1
- active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active site and lopinavir ritonavir treatment: 1
- active site and lpv lopinavir: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date